Eager to tout pivotal win, Omeros however keeps key parameters shrouded
Omeros has brought some stellar pivotal data to the FDA to build a case for its blood clot drug, narsoplimab. They just can’t say exactly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
